FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study). PMID 41238950 · Support Care Cancer · 2025-Nov-14 The study is an observational investigation of sarcopenia and paclitaxel-induced peripheral neuropathy in early-stage breast cancer. It is not a randomized controlled trial, lacks a definitive Phase III/IIIb or Phase II/III designation, and does not have a primary time-to-event efficacy endpoint as defined (e.g., OS, PFS). The primary outcome is a toxicity incidence, making it a secondary/safety analysis. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial. PMID 41238556 · Sci Rep · 2025-Nov-14 The study meets most inclusion criteria (oncology, human, randomized, drug intervention, time-to-event endpoint with HR, original result) but the trial phase is not explicitly stated in the provided metadata. The criteria require explicit confirmation of Phase III/IIIb or Phase II/III status, which is absent. Therefore, the record is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial. PMID 40932365 · Clin Cancer Res · 2025-Nov-14 The study is a phase II randomized trial with a drug intervention (atezolizumab) and reports primary efficacy results (pCR rates). It is excluded because it is not a phase III/IIIb or phase II/III trial as required, and it does not have a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is pathologic complete remission (pCR), a binary outcome, not a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial. PMID 40882625 · Med · 2025-Nov-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme. PMID 41248393 · BMJ Open · 2025-Nov-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. PMID 40888716 · N Engl J Med · 2025-Nov-13 The study is a randomized, Phase IV clinical trial with a primary time-to-event endpoint (composite of death or major adverse cardiovascular events) and a drug intervention (beta-blockers). However, it is excluded because it is not an oncology study, focusing on cardiovascular disease (myocardial infarction) rather than human malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of argon-helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer. PMID 41229194 · Acta Oncol · 2025-Nov-12 The record describes a randomized, open-label trial in oncology patients with drug intervention (PD-1 inhibitors) and reports time-to-event efficacy endpoints (OS, PFS). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided abstract or metadata; the deterministic review flagged phase evidence as unclear. Additionally, the intervention combines a drug (PD-1 inhibitor) with a non-drug procedure (argon-helium cryoablation), which may not fit the strict 'drug-containing intervention' criterion for a pharmacological comparison. Therefore, it is excluded due to insufficient evidence for the required trial phase and potential non-drug-only intervention component. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021). PMID 41225446 · BMC Cancer · 2025-Nov-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial. PMID 41225165 · J Cancer Surviv · 2025-Nov-12 Study is an original oncology RCT with time-to-event endpoints but does not meet the required drug intervention criterion; phase is also not established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma. PMID 41224871 · Sci Rep · 2025-Nov-12 The study is a randomized trial in oncology patients with a drug intervention, but the phase is not specified (no explicit mention of Phase III/IIIb or II/III). The primary endpoint is duration of neutropenia (a hematologic toxicity measure), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis. Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study. PMID 41222736 · Cancer Immunol Immunother · 2025-Nov-12 The record describes a randomized, controlled trial with a drug intervention and a primary time-to-event endpoint (PFS) in human oncology. However, the trial phase is not explicitly stated in the metadata (title, abstract, publication types, or MeSH terms). Eligibility requires explicit confirmation of Phase III/IIIb or Phase II/III status. Without this, the 'phase3_or_definitive' criterion cannot be established as true, rendering the record ineligible for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial. PMID 41222702 · Cancer Immunol Immunother · 2025-Nov-12 The report is an original randomized controlled trial in oncology (rectal cancer) with a drug intervention (PD-1 blockade). However, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The primary efficacy endpoint reported is tumor response rate, which is not a time-to-event outcome. The study also includes extensive preclinical/mechanistic components (cell lines, mouse models). Therefore, it does not meet the core eligibility criterion of having a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy: a study protocol of double-center, double-blind, randomized controlled trial. PMID 41219803 · Trials · 2025-Nov-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Bariatric metabolic surgery and cancer risk: Target trial emulation using iterative time distribution matching. PMID 41217501 · Biomol Biomed · 2025-Nov-11 The study is an observational retrospective cohort study using target trial emulation methodology, not a randomized controlled trial. The intervention is bariatric metabolic surgery, which is a surgical procedure, not a drug-containing intervention. The study is not in a Phase III/IIIb or Phase II/III randomized trial framework. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial. PMID 41213939 · Signal Transduct Target Ther · 2025-Nov-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Narrative therapy and resilience training improve recovery and survival after intersphincteric resection for low rectal cancer: a randomized trial. PMID 41191913 · Oncologist · 2025-Nov-11 The trial is a randomized, oncology study with a time-to-event endpoint (DFS/OS) and is the original report. However, the intervention is a psychosocial program (narrative therapy and resilience training), not a drug-containing intervention as required by the cohort definition. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer. PMID 41014160 · Oncologist · 2025-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. PMID 40720747 · Blood Adv · 2025-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study. PMID 41214650 · BMC Med · 2025-Nov-10 The study is excluded because the intervention is dietary (lycopene intake), not a drug-containing intervention. Additionally, while it is a randomized trial (PREDIMED), this specific analysis is a prospective cohort study within that trial, and the endpoint is cancer incidence as a preventive measure, not a primary/key secondary time-to-event efficacy endpoint for a drug in a definitive oncology trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of an exercise program on chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer individuals receiving taxanes: a randomized controlled trial. PMID 41212417 · Support Care Cancer · 2025-Nov-10 The study is a randomized controlled trial in oncology with a drug intervention, but it does not include a time-to-event efficacy endpoint (e.g., OS, PFS). It evaluates a non-drug intervention for managing chemotherapy side effects and quality of life, which falls outside the required scope. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol. PMID 41213710 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trial. PMID 41213708 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of ciprofol versus propofol on gastrointestinal motility in patients undergoing laparoscopic radical resection for colorectal cancer: study protocol for a randomised controlled trial. PMID 41213705 · BMJ Open · 2025-Nov-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. PMID 41207813 · Eur Urol Oncol · 2025-Nov-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study. PMID 41205003 · J Neurol · 2025-Nov-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Metformin on Cancer Survival Among Men Diagnosed with Advanced Prostate Cancer Treated with Androgen-Deprivation Therapy: Emulating a Target Trial. PMID 41228370 · Cancers (Basel) · 2025-Nov-06 The record describes an observational study (target trial emulation) using SEER-Medicare data, not a randomized clinical trial. While it is an oncology study in humans with a drug intervention (metformin) and a time-to-event endpoint (mortality), it fails the core requirement of being a report of a randomized trial (Phase III/IIIb or Phase II/III). The publication type is 'Journal Article', but the content is an observational analysis, not a report of a pre-specified randomized trial protocol or its results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Opioid-free anesthesia with quadratus lumborum block and Esketamine enhances postoperative recovery in laparoscopic colon cancer surgery: A randomized controlled trial. PMID 41198736 · Sci Rep · 2025-Nov-06 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. PMID 40737595 · Blood · 2025-Nov-06 The study is an oncology RCT reporting long-term overall survival results with a drug intervention. However, the phase is not explicitly stated in the provided metadata (e.g., publication type does not include 'Phase III' or similar), and the trial design compares two complex strategies rather than a direct drug-vs-placebo/standard-of-care comparison. The phase criterion cannot be definitively established as met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the novel simultaneous biplane versus in-plane imaging technique in ultrasound-guided biopsy: a prospective randomized multi-operator cross-over phantom study. PMID 40351114 · Diagn Interv Radiol · 2025-Nov-06 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of perioperative lidocaine application on inflammatory factors, immune function, and quality of early postoperative recovery in patients undergoing video-assisted thoracoscopic surgery: a randomized controlled trial. PMID 41194239 · Eur J Med Res · 2025-Nov-05 The record describes a randomized, drug-intervention trial in human lung cancer patients, but it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). The reported outcomes are biomarkers and quality-of-recovery measures. The trial phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. PMID 41193417 · Nat Commun · 2025-Nov-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial. PMID 41147407 · J Am Heart Assoc · 2025-Nov-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials. PMID 41222935 · JAMA Netw Open · 2025-Nov-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| E-Health Intervention for Fear of Cancer Recurrence: A Randomized Clinical Trial. PMID 41217757 · JAMA Netw Open · 2025-Nov-03 The study is a randomized clinical trial in oncology (colorectal cancer survivors) with primary results, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified, not meeting definitive phase criteria), does not involve a drug intervention (e-health/psychological intervention), and does not use a time-to-event efficacy endpoint (primary outcome is change in a patient-reported outcome score). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis. PMID 41206886 · JAMA Netw Open · 2025-Nov-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial. PMID 41196599 · JAMA Netw Open · 2025-Nov-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO). PMID 41184224 · Nat Commun · 2025-Nov-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia. PMID 40905823 · Cancer Epidemiol Biomarkers Prev · 2025-Nov-03 While the record describes a Phase III randomized trial with drug intervention in human oncology (childhood ALL), it does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The study's focus is on biomarkers of oxidative stress and neurodegeneration (CSF 8-hydroxydeoxyguanosine and total tau) as potential predictors of neurocognitive impairment, not survival or progression-free outcomes. Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. PMID 40864501 · Clin Cancer Res · 2025-Nov-03 The record describes a definitive randomized, controlled Phase III trial (TROPION-Breast01) with a drug intervention and time-to-event efficacy endpoints (PFS, OS) that resulted in an FDA approval. The full eligibility criteria are explicitly established in the abstract and metadata. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | no_km 0 Figure · 0 Panel · risk not_applicable |
| Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. PMID 40853871 · Clin Cancer Res · 2025-Nov-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial. PMID 40810606 · Cancer Epidemiol Biomarkers Prev · 2025-Nov-03 The study is a randomized, oncology, human trial, but it is excluded because it does not test a drug intervention (it tests screening modalities) and its primary endpoint is not a time-to-event efficacy outcome (OS, PFS, etc.) suitable for Kaplan-Meier analysis. The analysis models preclinical detectable phase duration, not survival or progression. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer. PMID 41123599 · Cancer Res Commun · 2025-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults: A Secondary Analysis of the ASPREE Randomized Clinical Trial. PMID 40996732 · JAMA Oncol · 2025-Nov-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial. PMID 40906462 · JAMA Oncol · 2025-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Blumgart Anastomosis Versus Invaginating Pancreatogastrostomy for Reconstruction after Pancreatoduodenectomy: A Randomized Controlled Trial. PMID 40747945 · Ann Surg · 2025-Nov-01 The trial is a randomized, oncology study in humans with original results, but it is ineligible because it lacks a drug-containing intervention and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The endpoints are postoperative complications and quality of life, not survival or progression metrics. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer. PMID 40693968 · Int J Surg · 2025-Nov-01 The trial is an original, randomized, Phase III oncology study with a drug-containing intervention. However, the reported primary and secondary endpoints are pathological complete response (pCR), objective response rate (ORR), disease control rate (DCR), and R0 resection rate, which are not time-to-event endpoints. No overall survival (OS), progression-free survival (PFS), or other time-to-event outcomes or associated Kaplan-Meier curves/hazard ratios are mentioned. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial. PMID 40536492 · Int J Cancer · 2025-Nov-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Quality of Life After Two Sequences of Total Neoadjuvant Treatment in Patients With Locally Advanced Rectal Cancer in the Randomized CAO/ARO/AIO-12 Phase 2 Trial. PMID 40409541 · Int J Radiat Oncol Biol Phys · 2025-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Ethiodized Oil-based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion. PMID 41288481 · Radiology · 2025-Nov The record describes a randomized controlled trial with drug interventions in hepatocellular carcinoma, reporting primary and secondary efficacy endpoints including time-to-event outcomes (PFS, OS) with hazard ratios and medians. Although the abstract does not explicitly state the trial phase (e.g., 'Phase III'), it is a definitive, multicenter, randomized trial comparing two drug-containing treatments with primary efficacy endpoints, meeting the criteria for a Phase II/III or definitive trial in this context. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Feasibility and Acceptability of a Mobile App Intervention to Promote Self-Efficacy and Resilience Among Breast Cancer Patients Undergoing Chemotherapy: A Pilot Randomized Controlled Trial. PMID 41217167 · Psychooncology · 2025-Nov The study is a pilot randomized controlled trial of a mobile app intervention for psychosocial support, not a definitive Phase III/IIIb or Phase II/III trial. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). While it involves breast cancer patients and is randomized, it does not meet the core eligibility criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |